Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

InnoCare and Keymed Approved to Start Trials of CD20xCD3 Bispecific

publication date: Sep 21, 2021

Beijing InnoCare and Chengdu's Keymed announced their IND for a CD20xCD3 bispecific antibody was cleared in China. CM355 binds to CD20 on tumor cells and CD3 on T cells using T-cell Directed Cellular Cytotoxicity (TDCC) to treat CD20+ B-cell malignancies. Non-Hodgkin lymphomas make up 80%-90% of all CD20+ B-cell malignancies. A joint venture formed by the two companies, Tiannuojiancheng Pharma, developed the bispecific. More details....

Stock Symbols: (HK: 09969) (HK: 02162)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.